Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylene blue + ozone
- Development stage
- Unknown
- Lead developer
- Assiut University
- Modality
- Small Molecules
- Administration
- Intravenous, Extracorporeal
01
Overview
methylene blue + ozone is a combination therapeutic approach investigated by Assiut University for the management of early sepsis. Methylene blue is a small molecule that acts as an inhibitor of inducible nitric oxide synthase (iNOS) and soluble guanylate cyclase, helping to counteract the vasodilation and hypotension associated with septic shock by reducing the overproduction of nitric oxide and cyclic guanosine monophosphate (cGMP). Ozone (O3) therapy is utilized for its potential immune-modulatory and antioxidant properties, which are thought to help regulate the inflammatory response in sepsis. This combination was evaluated in a Phase 4 clinical trial (NCT02910765) to assess its impact on clinical outcomes such as APACHE scores, duration of ICU stay, and mortality in adult patients with early sepsis.
- Other names
- ozone-Assiut University-sepsisMethylene Blue and Ozone in Early Sepsis
02
Targets
NOS1 (nNOS)sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on methylene blue + ozone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylene blue + ozone.